Clinical Trial Update: Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and efficacy of combining osimertinib with ipilimumab in patients with EGFR-mutated non-small cell lung cancer. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)
• Yervoy (ipilimumab)

Snippet

Sponsor: University of Utah | Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) | Phase 1 | Status: ACTIVE_NOT_RECRUITING